Progenity, Inc. announced the appointment of Adi Mohanty to company's Board of Directors. Adi Mohanty is an experienced biotech business leader with a track record of several successful product development and approvals followed by rapid commercialization. Previously, he served as CEO of BioTime. Adi formerly served as vice president at Transkaryotic Therapies, which was acquired by Shire PLC.